Highly active antiretroviral therapy prolongs the life of HIV-infected individuals, but it requires
lifelong treatment and results in cumulative toxicities and viral-escape mutants. Gene …

Intracellular antibodies (intrabodies) are recombinant antibody fragments that bind to target
proteins expressed inside of the same living cell producing the antibodies. The molecules …

AIDS is currently treated with a combination therapy of reverse transcriptase and protease
inhibitors. Recently, the FDA approved a drug targeting HIV-1 entry into cells. There are …

Progress in developing effective gene transfer approaches to treat HIV-1 infection has been
steady. Many different transgenes have been reported to inhibit HIV-1 in vitro. However …

Abstract Human Immunodeficiency Virus (HIV) infection remains a significant cause of
mortality globally. Though antiretroviral therapy has significantly reduced AIDS-related …

To interfere with cell function, many scientists rely on methods that target DNA or RNA due to
the ease with which they can be applied. Proteins are usually the final executors of function …

Integrase (IN) is the newest validated target against AIDS and retroviral infections. The
remarkable activity of raltegravir (Isentress®) led to its rapid approval by the FDA in 2007 as …

Advanced prostate cancers preferentially metastasize to bone, suggesting that this tissue
produces factors that provide a suitable microenvironment for prostate cancer cells …

In the past decade, a large number of intracellular antibodies (intrabodies) have been
developed for potential use as therapeutic agents. As antibodies can be generated against …

Chemokines have received increasing attention due to their inhibitory activities on human
immunodeficiency virus type-1 (HIV-1) and simian immunodeficiency virus (SIV) replication …